Navigation Links
Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Date:2/27/2008

MELBOURNE, Australia, Feb. 27 /PRNewswire/ -- The Walter and Eliza Hall Institute of Medical Research (WEHI) announced today that Abbott, a global, broad-based, healthcare company, Genentech, a leading biotechnology company based in South San Francisco and WEHI have joined in a tripartite research collaboration to discover new anti-cancer drugs.

"This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics," says Dr. Julian Clark, Head of Business Development at WEHI.

"We are excited to collaborate with Abbott and Genentech based on their expertise in apoptosis and strong track records in the development of small molecule drugs. We believe both will be excellent collaborators in bringing forward potential novel cancer therapeutics that target the apoptosis pathway," explains WEHI cancer researcher, Dr. David Huang.

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs. The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne. Financial terms of the collaboration will not be disclosed.

WEHI's director, Professor Suzanne Cory, emphasizes that "WEHI's first priority is to work to ensure that cancer patients benefit from the results of our fundamental research and all three parties in the collaboration are committed to the discovery and development of improved cancer treatments that enable patients to live longer and healthier lives."

Further information:

Dr. Julian Clark

Head Business Development WEHI: +61-3-9345-2612;

jclark@wehi.edu.au

Brad Allan

Communications Manager WEHI: +61-3-9345-2345

Mob +61-403036116


'/>"/>
SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
2. Recovery Resources Collaborates with Two Nonprofit Agencies for Children of Alcoholics Outreach Program
3. MU researchers to collaborate on $20 million project
4. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
5. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
6. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
7. Rosecrance and Chicagos Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
8. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
9. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
10. SAIC to Collaborate with UK Biometrics Institute
11. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... PALM CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... of cold therapy products, announced today the introduction of an innovative new design of ... the multipurpose pad so you get maximum comfort while controlling your pain while using ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... MENLO PARK, Calif. , Oct. 11, 2017 /PRNewswire/ ... a national scientific team that developed an innovative way ... and quantity of the delivery of new drugs. ... the 2017 Fall Clinical Dermatology Conference will show how ... Massachusetts General Hospital, Harvard Medical School used a suite ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
Breaking Medicine Technology: